UBI集團訊息

View More
UBI集團訊息
05082020
聯生藥抗體新藥UB-421皮下注射(SC)劑型獲台灣衛福部核准進行臨床I期試驗

台灣衛生福利部食品藥物管理署(TFDA)已核准其開發中抗體新藥UB-421之皮下注射(SC)劑型在HIV-1感染、但尚未接受任何藥物治療 (treatment naive)的患者上進行I 期臨床試驗。

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥抗體新藥UB-421皮下注射(SC)劑型獲台灣衛福部核准進行臨床I期試驗
View More
UBI集團訊息
04082020
聯亞集團董事長特助彭文君博士向社會大眾報告UBI /聯亞生技集團新冠肺炎研發進度

聯亞集團董事長特助彭文君博士向社會大眾報告UBI /聯亞生技集團新冠肺炎研發進度。

UBI group

廣譜新冠疫苗

精準設計型多重表為次單位疫苗UB-612

王長怡博士
more
聯亞集團董事長特助彭文君博士向社會大眾報告UBI /聯亞生技集團新冠肺炎研發進度
View More
UBI集團訊息
23072020
UBI/聯亞集團高精準設計新冠肺炎(COVID-19) 疫苗UB-612將於今年第三季展開第一期人體臨床試驗，TFDA 與CDE已派員進行駐廠監製

UB-612已列入醫藥品查驗中心（CDE）「COVID-19專案輔導計畫案件」，並於6月22日向台灣食品藥物管理署（TFDA）提出第一期人體臨床試驗申請

UBI group

廣譜新冠疫苗

精準設計型多重表為次單位疫苗UB-612

王長怡博士
more
UBI/聯亞集團高精準設計新冠肺炎(COVID-19) 疫苗UB-612將於今年第三季展開第一期人體臨床試驗，TFDA 與CDE已派員進行駐廠監製
View More
UBI集團訊息
30042020
联生药(扬州)生物医药有限公司通过药品生产许可证现场核查

2020年4月29日江苏药品监督管理局扬州直属分局徐剑秋局长带领专家组对联生药进行了为期两天的药品生产许可证现场核查。

UBI group
more
联生药(扬州)生物医药有限公司通过药品生产许可证现场核查
View More
UBI集團訊息
29042020
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection

They have received Investigational New Drug (IND) approval from Taiwan FDA to conduct a Phase 3 clinical trial with UB-421 in patients with multi-drug resistant (MDR) HIV-1 infection.

UBI group

愛滋病治療單株抗體UB-421
more
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
View More
UBI集團訊息
29042020
聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲台灣FDA核准執行

UB-421應用於治療多重抗藥性(multi-drug resistant (MDR)HIV感染病患之3期臨床試驗已獲台灣FDA核准執行

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲台灣FDA核准執行
View More
UBI集團訊息
29032020
Why coronavirus antibody testing in one Colorado town could provide a way forward

Testing in the ski town Telluride could allow for fewer restrictions nationwide.

UBI group
more
Why coronavirus antibody testing in one Colorado town could provide a way forward
View More
UBI集團訊息
28032020
「我們的任務是在這個非我所願的複雜混沌的時刻，展示自己最好的品格和行為。願我們與智慧和風度同行。」– Lawrence Bacow, President of Harvard University

UNITED BIOMEDICAL GROUP’S C19 COMPANY PARTNERS WITH SAN MIGUEL COUNTY, COLORADO TO BE FIRST IN NATION TO TEST AN ENTIRE COUNTY FOR COVID-19 WITH NEW ANTIBODY DIAGNOSTIC TEST

UBI group

王長怡博士
more
「我們的任務是在這個非我所願的複雜混沌的時刻，展示自己最好的品格和行為。願我們與智慧和風度同行。」– Lawrence Bacow, President of Harvard University
View More
UBI集團訊息
28032020
Frequently asked questions about UBI SARS-CoV2 ELISA

Frequently asked questions about UBI SARS-CoV2 ELISA

UBI group

王長怡博士
more
Frequently asked questions about UBI SARS-CoV2 ELISA
View More
UBI集團訊息
26032020
Why a Tiny Colorado County Can Offer COVID-19 Tests to Every Resident

There are advantages to having biotech executives as neighbors.

UBI group

王長怡博士
more
Why a Tiny Colorado County Can Offer COVID-19 Tests to Every Resident
View More
UBI集團訊息
26032020
為什麼一個科羅拉多州的小縣可以讓所有居民做新冠肺炎篩檢？

為什麼一個科羅拉多州的小縣可以讓所有居民做新冠肺炎篩檢？

UBI group

王長怡博士
more
為什麼一個科羅拉多州的小縣可以讓所有居民做新冠肺炎篩檢？
View More
UBI集團訊息
25032020
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers

An Investigational New Drug (IND) application from China National Medical Products Administration (NMPA) to conduct a phase 1 clinical trial with the company’s anti-IgE UB-221

UBI group

創新型IgE單株抗體UB-221
more
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers